



Entrez	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	B
Search	PubMed	for Swanson S and detection					Preview	Go	
		<input checked="" type="checkbox"/> Limits	Preview/Index	History	Clipboard	Details			

- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.

Entrez
PubMed

Search	Most Recent Queries	Time	Result
#49	Search Swanson S and detection Limits: Publication Date to 1999/08/25	14:33:18	<u>23</u>
#48	Search Swanson S and adenovirus Limits: Publication Date to 1999/08/25	14:32:39	<u>1</u>
#47	Search Swanson S Limits: Publication Date to 1999/08/25	14:32:29	<u>326</u>
#46	Search Mytych D Limits: Publication Date to 1999/08/25	14:32:08	<u>2</u>
#45	Search peptide linker and CKGKG Limits: Publication Date to 1999/08/25	14:26:12	<u>1195</u>
#44	Search peptide linker Limits: Publication Date to 1999/08/25	14:25:57	<u>1195</u>
#43	Search CKGKG Field: All Fields, Limits: Publication Date to 1999/08/25	14:25:36	<u>0</u>
#36	Search Lemon S and HCV Limits: Publication Date to 2000/12/23	09:59:45	<u>22</u>
#35	Search Lemon S Limits: Publication Date to 2000/12/23	09:46:17	<u>174</u>
#34	Search HCV replicon and tat Limits: Publication Date to 2000/12/23	09:43:39	<u>0</u>
#30	Search transactivation and HCV Field: All Fields, Limits: Publication Date to 2000/12/23	09:40:14	<u>13</u>
#28	Search Guo 2001 and HCV	09:14:26	<u>5</u>
#27	Search Guo 2000 and HCV	09:14:08	<u>4</u>
#25	Search Blight 2000 and hcv	09:08:04	<u>2</u>
#23	Search Bartenschlager 2000 and hcv	09:00:41	<u>4</u>
#20	Search Lohmann 1999 and HCV	08:46:00	<u>6</u>
#18	Search Lohmann 2001 and HCV	08:42:26	<u>7</u>
#16	Search Pietschamnn 2001 and self-replication Field: All Fields, Limits: Publication Date to 2000/12/23	08:40:04	<u>12</u>
#15	Search Pietschamnn 2001 and self-replication	08:39:23	<u>27</u>
#14	Search Pietschamnn 2001 and HCV RNA	08:39:12	<u>1059</u>
#13	Search Pietschamnn 2001 and HCV	08:38:37	<u>2577</u>
#11	Search Reynolds 1995 and HCV	08:37:24	<u>2</u>
#9	Search Reynolds 1996 and HCV	08:36:45	<u>1</u>

PubMed
Services

Related
Resources

```

=> "peptide linker"
    305983 "PEPTIDE"
    223298 "PEPTIDES"
    391308 "PEPTIDE"
        ("PEPTIDE" OR "PEPTIDES")
    14823 "LINKER"
    3477 "LINKERS"
    16810 "LINKER"
        ("LINKER" OR "LINKERS")
L5      359 "PEPTIDE LINKER"
        ("PEPTIDE" (W) "LINKER")

=> antigen and L1
    249705 ANTIGEN
    198079 ANTIGENS
    309817 ANTIGEN
        (ANTIGEN OR ANTIGENS)
L6      87 ANTIGEN AND L1

=> assay and L6
    300651 ASSAY
    128138 ASSAYS
    392648 ASSAY
        (ASSAY OR ASSAYS)
L7      4 ASSAY AND L6

=> adenovirus and L6
    19990 ADENOVIRUS
    2838 ADENOVIRUSES
    20494 ADENOVIRUS
        (ADENOVIRUS OR ADENOVIRUSES)
L8      0 ADENOVIRUS AND L6

```

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1997:238402 CAPLUS
DOCUMENT NUMBER: 126:220707
TITLE: Multimer compositions for conferring immunogenicity to a peptide
INVENTOR(S): Stanton, G. John; Hughes, Thomas K., Jr.; Smith, Eric M.
PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9705886	A1	19970220	WO 1996-US12632	19960805
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5807552	A	19980915	US 1995-511662	19950804
AU 9666452	A1	19970305	AU 1996-66452	19960805
PRIORITY APPLN. INFO.:			US 1995-511662	19950804
			WO 1996-US12632	19960805

ABSTRACT:
A multimer of monomers non-covalently held together by interactive ***peptide*** linkers if provided for the enhancement of the immunogenicity of a substance. These multimers are useful for stimulating or suppressing the immune system, detecting the presence of antibodies, bypassing MHC restriction in an animal, and the effective presentation of antigen, suppressing autoimmune disease, inducing cytokine production, adsorption, treating a defective immune system and for use as an adjuvant. The invention specifically describes multimers in which monomers are peptide sequences containing an HIV HP-6 epitope with left- and right-flanking linker sequences.

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1996:162202 CAPLUS
DOCUMENT NUMBER: 124:229436
TITLE: Production and characterization of bispecific single-chain antibody fragments
AUTHOR(S): De Jonge, Jan; Brissinck, Jan; Heirman, Carlo; Demanet, Christian; Leo, Oberdan; Moser, Muriel; Thielemans, Kris
CORPORATE SOURCE: Lab. Physiol., Med. Sch. Vrije Univ. Brussel, Brussels, B-1090, Belg.
SOURCE: Molecular Immunology (1995), 32(17/18), 1405-12
CODEN: MOIMD5; ISSN: 0161-5890
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
ABSTRACT:
We report the construction, expression and purification of a bispecific single-chain Fv antibody fragment produced in Escherichia coli. The protein possesses a dual specificity: the single-chain FvB1 portion is directed to the Idiotypic of BCL1 lymphoma cells, the single-chain Fv2C11 moiety binds to the CD3 marker on T cells. The two domains are joined by a flexible peptide ***linker***. Using Immobilized Metal Affinity Chromatog., the recombinant protein was purified from bacterial insol. membrane fractions. After refolding of the bispecific protein, it was affinity-purified. As demonstrated by flow

cytometry, both binding sites are retained in the refolded protein. Retargeted cytotoxicity and T cell proliferation **assays** further prove the biol. activity and specificity of the bispecific single-chain Fv. Thus, these bispecific mols. show a potential antitumor activity.